MAPT and Alzheimer disease: For example, DeVos et al. identified an AON that targeted and degraded tau mRNA.[266] They demonstrated that this AON can selectively reduce the tau mRNA and tau proteins in mouse AD model as shown by qRT‐PCR and Western blot, respectively.